NCT00002880View on ClinicalTrials.gov

Etoposide in Treating Patients With Relapsed Non-Hodgkin's Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

November 30, 1996

Primary Completion Date

January 31, 2001

Study Completion Date

January 31, 2008

Conditions
Lymphoma
Interventions
DRUG

Etoposide phosphate

50 mg PO q day for 21 days; repeat every 28 days escalate dose to 100 mg PO q day if ANC remains greater than 1500/microliter during cycle 1: no specified maximum of cycles if PR or CR

Trial Locations (4)

55455

University of Minnesota Cancer Center, Minneapolis

63110

Washington University Barnard Cancer Center, St Louis

07503

St. Joseph's Hospital and Medical Center, Paterson

27157-1082

Comprehensive Cancer Center of Wake Forest University Baptist Medical Center, Winston-Salem

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Alliance for Clinical Trials in Oncology

OTHER